Primordial role of CD34⁺38⁻ cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation

Abstract

Summary. In order to better define which cell subset contained in graft products might be the most predictive of haemopoietic recovery following autologous blood cell transplantation (ABCT), the relationships between the amounts of reinfused mononuclear cells (MNC), CFU-GM, total CD34 þ cells and their CD33 and CD38 subsets, and the successive stages of trilineage engraftment kinetics, were studied in 45 cancer patients, using the Spearman correlation test, a linear regression model and a log-inverse model. No relationship was found between the infused numbers of MNC, CD33 þ and CD33¹ subsets observed and the numbers of days to reach predetermined absolute neutrophil (ANC), platelet and reticulocyte counts. The infused numbers of CFU-GM, CD34þ and CD34þ cells correlated inconstantly with haemopoietic recovery parameters. The strongest and the most constant correlations were significantly observed between the infused numbers of CD34 þ 38 ¹ cells and each trilineage engraftment parameter. The log-inverse model determined a threshold dose of 0·05 × 10 6 (¼ 5 × 10 4 ) CD34 þ 38 ¹ cells/kg, below which the trilineage engraftment kinetics were significantly slower and unpredictable. Post-transplant TBI-conditioning regimens increased the low cell dose-related delay of engraftment kinetics whereas post-transplant administration of haemopoietic growth factors (HGF) seemed to abrogate this delay. This would justify clinical use of HGF only in patients transplanted with CD34 þ 38 ¹ cell amounts lower than the proposed threshold value.This study suggests that the CD34 þ 38 ¹ subpopulation, although essentially participating in late complete haemopoietic recovery, is also composed of committed progenitor cells involved in early trilineage engraftment.

Adult Refractory Chronic Idiopathic Thrombocytopenic Purpura: Can Dapsone Be Proposed as Second‐line Therapy?

“…These findings are consistent with those of Henon et al (1998), including the suggested threshold dose of 0·05 × 10 6 /kg CD34 þ CD38 ¹ cells for rapid engraftment: 4/4 patients transplanted with at least this dose achieved rapid neutrophil engraftment (< 11 d), compared to only 4/10 patients transplanted with less than this. Several authors have subdivided the CD34 þ CD38 ¹ population on the basis of HLA-DR expression (Huang & Terstappen, 1994;Rusten et al, 1994).…”

“…From these new experiments we believe that a false positive reaction for CD7 can be excluded in our previous data by our routine flowcytometric analysis. Henon et al (1998) described the role of CD34 þ CD38 ¹ cells in early and late trilineage engraftment after PBSC transplantation, and identified better correlation with haemopoietic recovery of CD34 þ CD38 ¹ than total CD34 þ cells. We report similar findings in a group of patients undergoing peripheral blood stem cell (PBSC) transplantation in Belfast City Hospital, Belfast, Northern Ireland, and in addition include analysis of the relationship with post-transplant recovery of the CD34 þ CD38 ¹ HLA-DR ¹ population.…”

“…Several authors have subdivided the CD34 þ CD38 ¹ population on the basis of HLA-DR expression (Huang & Terstappen, 1994;Rusten et al, 1994). Henon et al (1998) postulate that HLA-DR expression might identify committed and uncommitted progenitors, with the less differentiated CD34 þ CD38 ¹ HLA-DR ¹ cells contributing to late engraftment. Our study does not support this hypothesis and demonstrated a significant contribution of CD34 þ CD38 ¹ HLA-DR ¹ cells to early engraftment and better correlation than with the CD34 þ or CD34 þ CD38 ¹ populations.…”

Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study

“…Eligible patients had histologically confirmed CD20+ B-cell lymphomas (according to the World Health Organization classification) in progressive disease or partial remission after at least one line of treatment. Patients had to be at least 18 years old, have lesions measurable on 18 FDG-PET/CT, World Health Organization performance status ≤ 2, absolute neutrophil count (ANC) ≥ 1500/μl, platelet count ≥ 100.000/μl and a life expectancy of at least 6 months.…”

Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose

“…14,15 Here, the correlation of cell dose with engraftment kinetics appears to be even more pronounced when considering the CD34 ϩ CD38 Ϫ subset. 16 There are fewer studies that analyze the effects of growth factor use, CD34 ϩ dose or other patient or donor characteristics on engraftment kinetics in recipients of T celldepleted (TCD) marrow grafts. However, it would appear that neutrophil engraftment is accelerated with growth factor treatment in this setting as well.…”